Sekmek, S. Et Al. 2025. Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study. Immunotherapy , vol.17, no.9 , 649-655.

Sekmek, S., BÖLEK, H., Kuzu, O. F., Camoz, E. S., Sim, S., Karakaş, H., ... Guliyev, M.(2025). Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study. Immunotherapy , vol.17, no.9, 649-655.

Sekmek, Serhat Et Al. "Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study," Immunotherapy , vol.17, no.9, 649-655, 2025

Sekmek, Serhat Et Al. "Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study." Immunotherapy , vol.17, no.9, pp.649-655, 2025

Sekmek, S. Et Al. (2025) . "Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study." Immunotherapy , vol.17, no.9, pp.649-655.

@article{article, author={Serhat Sekmek Et Al. }, title={Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study}, journal={Immunotherapy}, year=2025, pages={649-655} }